Clinical Trial Detail

NCT ID NCT04145297
Title Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas (UTAH)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Utah
Indications

gastrointestinal system cancer

Therapies

Hydroxychloroquine + Ulixertinib

Age Groups: adult senior

Additional content available in CKB BOOST